Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
The Journal of Rheumatology|November 5, 2013
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusEllen M Ginzler, Daniel J Wallace, Joan T Merrill, et al.
Arthritis Care & Research|August 30, 2022
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus NephritisCristina Arriens, Y K Onno Teng, Ellen M Ginzler, et al.
Annals of the Rheumatic Diseases|May 3, 2012
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsSusan Manzi, Jorge Sánchez-Guerrero, Joan T Merrill, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
Lancet (London, England)|May 10, 2021
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialBrad H Rovin, Y K Onno Teng, Ellen M Ginzler, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 12, 2017
The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance ProgramPeter M Izmirly, Isabella Wan, Sara Sahl, et al.
Arthritis Care & Research|July 26, 2018
The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York CountyPeter M Izmirly, Jill P Buyon, Isabella Wan, et al.
Arthritis and Rheumatism|November 13, 2002
Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosusBetty P Tsao, Rita M Cantor, Jennifer M Grossman, et al.
Rheumatology (Oxford, England)|December 20, 2022
Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance ProgramGhadeer Hasan, Elizabeth D Ferucci, Jill P Buyon, et al.
Arthritis and Rheumatism|August 29, 2009
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusDaniel J Wallace, William Stohl, Richard A Furie, et al.
Pageof 13